TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12296779

Group type: EXPERIMENTAL
Intervention: 0.05% cetylpyridinium chloride (CPC)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 0.3% triclosan
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control fluoride
Number of subjects: 76
Study: 9917438

Group type: EXPERIMENTAL
Intervention: Amoxicillin (750 mg once daily)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Penicillin V (250 mg three times a day)
Number of subjects: 152
Study: 7493209

Group type: EXPERIMENTAL
Intervention: High-intensity strength training program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 100
Study: 31147378

Group type: EXPERIMENTAL
Intervention: Co-created educational intervention (12 interactive sessions, 2 hours each, from November 2013 to April 2014)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Regular training (control group)
Number of subjects: 24
Study: 30412222

Group type: EXPERIMENTAL
Intervention: Sunitinib (50mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25663609

Group type: EXPERIMENTAL
Intervention: Dietary total antioxidant capacity (upper quintile)
Number of subjects: 7447

Group type: EXPERIMENTAL
Intervention: Intake of all studied vitamins
Number of subjects: 7447
Study: 25304727

Group type: EXPERIMENTAL
Intervention: Low-dose interleukin-2 (IL-2) + interferon-α (IFN-α)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 310
Study: 22789797

Group type: EXPERIMENTAL
Intervention: Combined nutraceutical containing Orthosiphon stamineus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (calcium-channel blockers or angiotensin converting enzyme inhibitors)
Number of subjects: 0
Study: 19786345

Group type: EXPERIMENTAL
Intervention: Early palliative care intervention
Number of subjects: 315

Group type: COMPARATOR
Intervention: Routine oncology care
Number of subjects: 315
Study: 17479929

Group type: EXPERIMENTAL
Intervention: Show-up identification
Number of subjects: 160

Group type: COMPARATOR
Intervention: Line-up identification
Number of subjects: 160
Study: 15499224

Group type: EXPERIMENTAL
Intervention: 3-month formulation
Number of subjects: 131

Group type: COMPARATOR
Intervention: 28-day formulation
Number of subjects: 131
Study: 11495171

Group type: EXPERIMENTAL
Intervention: Parent training intervention
Number of subjects: 238

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 238
Study: 9498316

Group type: EXPERIMENTAL
Intervention: Addiction Severity Index (ASI)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Trauma History Questionnaire (THQ)
Number of subjects: 110
Study: 7991130

Group type: EXPERIMENTAL
Intervention: CMT1 nerves
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other causes of neuropathy (matched control group)
Number of subjects: 0
Study: 2846480

Group type: EXPERIMENTAL
Intervention: Superfractionated radiation (3 times a day to a total dose of 4760 cGy)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard daily treatment (to 4000 cGy)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Superfractionated radiation
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard daily treatment
Number of subjects: 76
Study: 4919554

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (Cyclokapron) 1 g four times a day for the first four days of menstruation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 30781758

Group type: EXPERIMENTAL
Intervention: Prev@cib program (experimental group)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 660
Study: 28357598

Group type: EXPERIMENTAL
Intervention: Er:YAG laser; 1.2 W
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Er:YAG laser; 0.5 W
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no laser treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Superficial dentin groups (all treatments)
Number of subjects: 0
Study: 24750286

Group type: EXPERIMENTAL
Intervention: Nurse-family partnership intervention
Number of subjects: 61

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 61
Study: 23803136

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg initial dose, followed by 75 mg/day for 90 days) plus aspirin (75 mg/day for 21 days)
Number of subjects: 5170

Group type: COMPARATOR
Intervention: Aspirin (75 mg/day for 90 days)
Number of subjects: 5170

Group type: EXPERIMENTAL
Intervention: Clopidogrel-aspirin group
Number of subjects: 5170

Group type: COMPARATOR
Intervention: Aspirin group
Number of subjects: 5170
Study: 21693699

Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin 10 mg/20 mg in the morning (within 1 hour of breakfast)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Ezetimibe/simvastatin 10 mg/20 mg in the evening (within 1 hour of dinner)
Number of subjects: 171
Study: 18300746

Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) treatment
Number of subjects: 47

Group type: COMPARATOR
Intervention: Isotonic NaCl (control)
Number of subjects: 47
Study: 16608780

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 0.75 g loading dose before surgery and 250 mg/h during surgery (total 1.5 g)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Tranexamic acid (TA) and Saline solution (control)
Number of subjects: 76
Study: 14600575

Group type: EXPERIMENTAL
Intervention: Intermittent interleukin-2 (IL-2) therapy
Number of subjects: 15
Study: 12847572

Group type: EXPERIMENTAL
Intervention: Doxazosin GITS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxazosin standard formulation
Number of subjects: 0
Study: 8782296

Group type: EXPERIMENTAL
Intervention: Kurume solution with 1% albumin (group 2)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: GIK solution with 1% albumin (group 4)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Kurume solution without albumin (group 1)
Number of subjects: 47

Group type: COMPARATOR
Intervention: GIK solution without albumin (group 3)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Groups with albumin (group 2 and group 4)
Number of subjects: 47
Study: 1729820

Group type: EXPERIMENTAL
Intervention: iopamidol (Isovue‐370)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ioversol (Optiray‐320)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: iohexol (Omnipaque‐350)
Number of subjects: 20

Group type: COMPARATOR
Intervention: All contrast media
Number of subjects: 20
Study: 6148872

Group type: EXPERIMENTAL
Intervention: Nadolol (mean dosage, 87 +/- 43 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31903773

Group type: EXPERIMENTAL
Intervention: Personalised educational sessions for carers
Number of subjects: 197

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 197
Study: 30632333

Group type: EXPERIMENTAL
Intervention: 4 strand double modified Kessler repair with 1 knot
Number of subjects: 100

Group type: COMPARATOR
Intervention: 4 strand double modified Kessler repair with 2 knot
Number of subjects: 100
Study: 27093774

Group type: EXPERIMENTAL
Intervention: Skilled operator using three-step etch-and-rinse (Optibond FL)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Skilled operator using one-step self-etch (G-Bond)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Unexperienced operators using three-step etch-and-rinse (Optibond FL)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Unexperienced operators using one-step self-etch (G-Bond)
Number of subjects: 42
Study: 24820248

Group type: EXPERIMENTAL
Intervention: 2-week meditation program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 0
Study: 22574370

Group type: EXPERIMENTAL
Intervention: Microscopic varicocelectomy (MV)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Laparoscopic varicocelectomy (LV)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both MV and LV
Number of subjects: 72
Study: 21031578

Group type: EXPERIMENTAL
Intervention: rAAV1.tMCK.hSGCA (3.25 × 10¹¹ vector genomes)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 3
Study: 18575278

Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Acetaminophen (1000 mg)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 210
Study: 15031448

Group type: EXPERIMENTAL
Intervention: Increasing film-focus distance (FFD) from 100 cm to 130 cm
Number of subjects: 0

Group type: COMPARATOR
Intervention: FFD of 100 cm
Number of subjects: 0
Study: 12368364

Group type: EXPERIMENTAL
Intervention: Spironolactone (12.5-50 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no spironolactone)
Number of subjects: 30
Study: 9848801

Group type: EXPERIMENTAL
Intervention: multiple tailored letters with self‐help guide
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: multiple tailored letters only
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: a single tailored letter with a self‐help guide
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: a single tailored letter only
Number of subjects: 752

Group type: COMPARATOR
Intervention: nontailored intervention
Number of subjects: 752
Study: 7862911

Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Milacemide (400 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 2570234

Group type: EXPERIMENTAL
Intervention: Early suckling
Number of subjects: 4227

Group type: COMPARATOR
Intervention: Control group (no early suckling)
Number of subjects: 4227
Study: 322921

Group type: EXPERIMENTAL
Intervention: Carbidopa (100 mg/day for 6 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Alpha methyldopa (1.0 gm) with benserazide (1.5 gm)
Number of subjects: 10
Study: 28650189

Group type: EXPERIMENTAL
Intervention: Value LAP condition during low intensity exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition during low intensity exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Value LAP condition during calming amusement park rides
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Value LAP condition during exciting amusement park rides
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition during calming amusement park rides
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition during exciting amusement park rides
Number of subjects: 0
Study: 27724978

Group type: EXPERIMENTAL
Intervention: Copenhagen Triage Algorithm (CTA)
Number of subjects: 50000

Group type: COMPARATOR
Intervention: Danish Emergency Process Triage (DEPT)
Number of subjects: 50000
Study: 24704626

Group type: EXPERIMENTAL
Intervention: Fenofibric acid (FA) therapy alone
Number of subjects: 2385

Group type: EXPERIMENTAL
Intervention: Fenofibric acid (FA) and statin therapy
Number of subjects: 2385

Group type: COMPARATOR
Intervention: Statin therapy alone
Number of subjects: 2385
Study: 22520120

Group type: EXPERIMENTAL
Intervention: Rotavin-M1 (10(6.3)FFU/dose) - 2 doses, 2 months apart (Group 2H)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Rotavin-M1 (10(6.0)FFU/dose) - 2 doses, 2 months apart (Group 2L)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Rotavin-M1 (10(6.3)FFU/dose) - 3 doses, 1 month apart (Group 3H)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Rotavin-M1 (10(6.0)FFU/dose) - 3 doses, 1 month apart (Group 3L)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Rotarix™ (10(6.5)CCID(50)/dose) - 2 doses, 1 month apart
Number of subjects: 160

Group type: COMPARATOR
Intervention: Rotarix™
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Rotavin-M1
Number of subjects: 160
Study: 20329567

Group type: EXPERIMENTAL
Intervention: human derived FSH
Number of subjects: 115

Group type: COMPARATOR
Intervention: recombinant FSH
Number of subjects: 115
Study: 18418975

Group type: EXPERIMENTAL
Intervention: Egb761 (Ginkgo biloba extract) with chemotherapy (4 cycles of PA protocol)
Number of subjects: 60
Study: 16192262

Group type: EXPERIMENTAL
Intervention: Diet enriched with probiotics (6 x 10^9 CFU of Streptococcus thermophilus, Bifidobacterium lactis, Lactobacillus acidophilus) and 10 mg of zinc/day
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Diet enriched with probiotics and zinc
Number of subjects: 65
Study: 12814810

Group type: EXPERIMENTAL
Intervention: Yasmin (30 microg ethinylestradiol and 3 mg drospirenone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Marvelon (30 microg ethinylestradiol and 150 microg desogestrel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both Yasmin and Marvelon
Number of subjects: 0
Study: 11103175

Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microgram kg‐1
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Morphine 0.1 mg kg‐1
Number of subjects: 180

Group type: COMPARATOR
Intervention: i.v. saline (Control)
Number of subjects: 180
Study: 8973752

Group type: EXPERIMENTAL
Intervention: Plasma neuropeptide Y (NPY) levels
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Angiotensin II
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Total cholesterol
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: LDL-cholesterol
Number of subjects: 220
Study: 1731027

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy with bacteriologic efficacy of 100%
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy with bacteriologic efficacy of 27% (consistent with no antibacterial therapy)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Tympanocentesis and culture before and during therapy
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Tympanocentesis before therapy and assessment of clinical efficacy
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: No tympanocentesis and assessment of clinical efficacy
Number of subjects: 293
Study: 6690196

Group type: EXPERIMENTAL
Intervention: Pentagastrin 100 ng h‐1 kg‐1
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Pentagastrin 500 ng h‐1 kg‐1
Number of subjects: 9
Study: 30741864

Group type: EXPERIMENTAL
Intervention: New prediction equation 1 using height and body mass as covariates
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: New prediction equation 2 using body composition parameters
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Average resting metabolic rate (RMR) assessment
Number of subjects: 66

Group type: COMPARATOR
Intervention: Comparison of body composition across sports
Number of subjects: 66

Group type: COMPARATOR
Intervention: Correlation of RMR with physical parameters
Number of subjects: 66
Study: 30229683

Group type: EXPERIMENTAL
Intervention: Banxia Xiexin decoction
Number of subjects: 27

Group type: COMPARATOR
Intervention: CPT‐11
Number of subjects: 27
Study: 26224242

Group type: EXPERIMENTAL
Intervention: Distance learning (n=53)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Face to face training (Control group, n=44)
Number of subjects: 97
Study: 24809787

Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 60

Group type: COMPARATOR
Intervention: McCoy laryngoscope
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 60
Study: 22994106

Group type: EXPERIMENTAL
Intervention: Intravenous mexidol (300 mg daily for 2 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment of primary open-angle glaucoma
Number of subjects: 0
Study: 20038730

Group type: EXPERIMENTAL
Intervention: Platinum-doublet chemotherapy for three cycles followed by gefitinib 250 mg orally once daily, until disease progression (arm B)
Number of subjects: 604

Group type: COMPARATOR
Intervention: Platinum-doublet chemotherapy up to six cycles (arm A)
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Platinum-doublet chemotherapy for three cycles followed by gefitinib 250 mg orally once daily (arm B)
Number of subjects: 604
Study: 17572319

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% (500 mg in 48 hours via elastomeric pump)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Normal saline (250 mL as placebo)
Number of subjects: 96
Study: 16175565

Group type: COMPARATOR
Intervention: Treatment for SAD (exact intervention details not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonresponders to treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients who dropped out of the study
Number of subjects: 0
Study: 11804991

Group type: EXPERIMENTAL
Intervention: Reboxetine (8 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 10825863

Group type: EXPERIMENTAL
Intervention: Colgate Total Toothpaste
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 19
Study: 8566936

Group type: EXPERIMENTAL
Intervention: Rilmenidine (1 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2884856

Group type: EXPERIMENTAL
Intervention: Doxazosin 12 mg (range 1 to 16)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Atenolol 91.8 mg (range 50 to 100)
Number of subjects: 126
Study: 29579254

Group type: EXPERIMENTAL
Intervention: Tendril plot visualization of adverse events
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 27208464

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 60
Study: 26654215

Group type: EXPERIMENTAL
Intervention: Novel Patient Interaction (NPI) - 1-hour small-group session with a patient discussing options counseling and decision to terminate pregnancy.
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control - Standard curriculum only.
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: NPI
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control
Number of subjects: 135
Study: 23981369

Group type: EXPERIMENTAL
Intervention: Acupuncture (2 sessions/week for 4 weeks)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Sham acupuncture (control group)
Number of subjects: 127
Study: 20962916

Group type: EXPERIMENTAL
Intervention: Caffeine and epigallocatechin-3-gallate (EGCG) with exercise (EX-Act)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo with exercise (EX-PL)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Caffeine and epigallocatechin-3-gallate (EGCG) without exercise (NEX-Act)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo without exercise (NEX-PL)
Number of subjects: 27
Study: 18156639

Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol for replacement therapy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 20004545

Group type: EXPERIMENTAL
Intervention: Decision aids (DAs) with additional information about competing health risks
Number of subjects: 663

Group type: COMPARATOR
Intervention: Decision aids (DAs) without additional information about competing health risks
Number of subjects: 663
Study: 15695960

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12218723

Group type: EXPERIMENTAL
Intervention: EMTDS 0.025 mg/day
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: EMTDS 0.05 mg/day
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: EMTDS 0.075 mg/day
Number of subjects: 355

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study: 9468457

Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion (2 ng Ang II/kg per min)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham infusion
Number of subjects: 15
Study: 8194508

Group type: EXPERIMENTAL
Intervention: 100 mg elemental zinc (as zinc sulphate) for 7 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 50 mg elemental zinc (as zinc sulphate) for 7 days
Number of subjects: 24
Study: 3285809

Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 105

Group type: COMPARATOR
Intervention: Tobramycin-clindamycin
Number of subjects: 105
Study: 11171824

Group type: EXPERIMENTAL
Intervention: Duodenal lipid infusion (L-2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CCK-A antagonist dexloxiglumide (5 mg/kg/h)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30222021

Group type: EXPERIMENTAL
Intervention: Intraoral bitewing radiographs (BTW)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Periapical radiographs (PA)
Number of subjects: 241
Study: 30249507

Group type: EXPERIMENTAL
Intervention: Ustekinumab (260 mg for patients weighing 35-55 kg, 390 mg for patients weighing >55 kg and ≤85 kg, and 520 mg for patients weighing >85 kg) followed by subcutaneous injections of 90 mg every 8 weeks.
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo intravenous infusion at week 0 followed by subcutaneous injections every 8 weeks.
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 27305046

Group type: EXPERIMENTAL
Intervention: Early clinical stability
Number of subjects: 580
Study: 25407020

Group type: EXPERIMENTAL
Intervention: Same-day opioid substitution treatment (methadone)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Baseline questionnaires at recruitment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Regular health evaluation paired with low-barrier access to treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 3 month follow-up
Number of subjects: 20
Study: 22308967

Group type: EXPERIMENTAL
Intervention: Self-leadership training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 19858703

Group type: EXPERIMENTAL
Intervention: EndoBarrier Gastrointestinal Liner
Number of subjects: 41

Group type: COMPARATOR
Intervention: Diet control group
Number of subjects: 41
Study: 18035193

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg PO QD for 24 months
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 16303729

Group type: EXPERIMENTAL
Intervention: Combination therapy with benazepril 5 mg and losartan 25 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Benazepril alone (higher dose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Losartan alone (higher dose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 24